2014
DOI: 10.1038/nature13737
|View full text |Cite
|
Sign up to set email alerts
|

Structural basis for the inhibition of the eukaryotic ribosome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

20
449
1
1

Year Published

2015
2015
2023
2023

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 451 publications
(471 citation statements)
references
References 76 publications
(51 reference statements)
20
449
1
1
Order By: Relevance
“…Furthermore, reconstitution of translation in the presence of the elongation inhibitor cycloheximide results in relative movement of the ribosome on the dicistrovirus IRES by six nucleotides, indicating that two cycles of elongation have occurred (6,11,18,19). Cycloheximide inhibits translation by binding to the ribosomal E site, and as such, these observations are consistent with a model in which the IRES initially occupies the P site to direct translation from the A site (18,32). In light of the recent highresolution structural data presenting evidence that initial ribosome binding positions the PKI domain of the IRES in the ribosomal A site, we reevaluated the initial translocation steps of ribosomes assembled on the IRES (20,22).…”
Section: A6554 and A6576 Contribute To Ires-mediated Translation Andsupporting
confidence: 74%
See 1 more Smart Citation
“…Furthermore, reconstitution of translation in the presence of the elongation inhibitor cycloheximide results in relative movement of the ribosome on the dicistrovirus IRES by six nucleotides, indicating that two cycles of elongation have occurred (6,11,18,19). Cycloheximide inhibits translation by binding to the ribosomal E site, and as such, these observations are consistent with a model in which the IRES initially occupies the P site to direct translation from the A site (18,32). In light of the recent highresolution structural data presenting evidence that initial ribosome binding positions the PKI domain of the IRES in the ribosomal A site, we reevaluated the initial translocation steps of ribosomes assembled on the IRES (20,22).…”
Section: A6554 and A6576 Contribute To Ires-mediated Translation Andsupporting
confidence: 74%
“…5, lane 11). Whereas previous interpretations of the biochemical data indicated that cycloheximide inhibits translation when a deacylated tRNA is bound in the E site (18), given the recent structural data indicating that cycloheximide binds to the E site, where the acceptor end of a tRNA normally resides (32), an alternate interpretation is that cycloheximide induces a premature block in the initial steps of IRES translation by binding to the ribosome and inhibiting translocation with the IAPV PKI domain in the E site and the first aminoacyl-tRNA in the P site. Thus, occupancy of the IAPV tRNAlike PKI domain in the E site can still accommodate cycloheximide binding, leading to inhibition of ribosome translocation.…”
Section: A6554 and A6576 Contribute To Ires-mediated Translation Andmentioning
confidence: 96%
“…We have found that DuL11AB cells are not hypersensitive toward anisomycin, a specific inhibitor of peptide bond formation. 46,47 This suggests that the peptidyltransferase reaction is not affected by the lack of the uL11 protein. Complementary, none of the perturbations within the GAC was shown to exert an effect on the peptidyl transferase Figure 5.…”
Section: Ul11 Involvement In Ribosomal Speed and Accuracymentioning
confidence: 98%
“…CHX is a small-molecule translation inhibitor that has been a staple of experimental approaches to the study of translation for decades. The exact mechanism of this inhibition, however, is not completely understood, with recent studies suggesting that CHX binds to a ribosome's E-site along with a deacylated tRNA to block further translocation [19,20]. The majority of the rapidly growing body of ribosome profiling experiments in yeast have followed this original CHX-pretreatment protocol [13,[21][22][23][24][25][26][27][28][29][30].…”
Section: Introductionmentioning
confidence: 99%